header
Image from OpenLibrary

Circulating microRNAs 210 and 23b as potential novel biomarkers for bladder cancer / Amal Bahgat Fakhry ; Supervised Omnya Ahmed Youssef , Amr Salah Eldin Fayyad , Mona Mohammad Fathy

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Amal Bahgat Fakhry , 2020Description: 176 P. ; 25cmOther title:
  • دراسة احتمالية كون احماض الريبونيوكليك الدقيقه بى 210 و 23 الموجوده بالدم كدلالات اورام جديده لتشخيص سرطان المثانه [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology Summary: Background: Bladder carcinoma (BC) is one of the most common and lethal malignant tumors worldwide. MicroRNAs are involved in the epigenetic mechanisms implicated in BC molecular pathogenesis. Measuring the levels of the circulating miRNAs to be used as biomarkers for malignancies has recently been investigated in the hope of identifying unique miRNA signatures in human tumors. Two microRNAs have been selected in this study; miRNA 210 and miRNA 23b. Aim of the study: To identify miRNA 210 and miRNA 23b relative expression levels in the sera of BC patients. Methods: This study was conducted on 93 Egyptian adults who were divided into three groups: Group I: included 31 newly diagnosed patients with bladder cancer. Group II: included the same 31 patients of group I after 6 months from their medical and/or surgical treatment, Group III: included 31 apparently healthy subjects as a control group. They were subjected to routine laboratory investigations and gene expression analysis for miRNA 210 and miRNA 23b using quantitative SYBR Green reverse-transcription Real-Time polymerase chain reaction. Results: It was found that median values of fold change (FC) of miRNA 210 were significantly higher in the sera of BC patients than in the control group (p =0.012). While there was no statistically significant difference in the median values of fold change (FC) of miRNA 23b between BC patients and the healthy control group p= 0.188
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.07.Ph.D.2020.Am.C (Browse shelf(Opens below)) Not for loan 01010110080915000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.07.Ph.D.2020.Am.C (Browse shelf(Opens below)) 80915.CD Not for loan 01020110080915000

Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology

Background: Bladder carcinoma (BC) is one of the most common and lethal malignant tumors worldwide. MicroRNAs are involved in the epigenetic mechanisms implicated in BC molecular pathogenesis. Measuring the levels of the circulating miRNAs to be used as biomarkers for malignancies has recently been investigated in the hope of identifying unique miRNA signatures in human tumors. Two microRNAs have been selected in this study; miRNA 210 and miRNA 23b. Aim of the study: To identify miRNA 210 and miRNA 23b relative expression levels in the sera of BC patients. Methods: This study was conducted on 93 Egyptian adults who were divided into three groups: Group I: included 31 newly diagnosed patients with bladder cancer. Group II: included the same 31 patients of group I after 6 months from their medical and/or surgical treatment, Group III: included 31 apparently healthy subjects as a control group. They were subjected to routine laboratory investigations and gene expression analysis for miRNA 210 and miRNA 23b using quantitative SYBR Green reverse-transcription Real-Time polymerase chain reaction. Results: It was found that median values of fold change (FC) of miRNA 210 were significantly higher in the sera of BC patients than in the control group (p =0.012). While there was no statistically significant difference in the median values of fold change (FC) of miRNA 23b between BC patients and the healthy control group p= 0.188

Issued also as CD

There are no comments on this title.

to post a comment.